These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 31856446)

  • 1. [The clinical observation of serum specific biomarkers in patients with chronic graft-versus-host disease].
    Chen T; Li XP; Zhang C; Kong PY; Gao QG; Tang L; Wang R; Yang SJ; Gao L; Liu Y; Gao L; Feng YM; Rao J; Peng XG; Zhang X
    Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):948-952. PubMed ID: 31856446
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical study of the cytokine panel in the diagnosis of ocular chronic graft-versus-host disease].
    Cheng XJ; Ji R; Huan RH; Huang SQ; Fan W; Zhao YC; Yuan RD; Wang XQ; Zhang X
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):242-248. PubMed ID: 38716595
    [No Abstract]   [Full Text] [Related]  

  • 3. [The Expression and Significance of Serum Protein ROCK2 in Patients with Chronic Graft-Versus-Host Disease].
    Tang P; Zheng CH; Dong ZK; Xie MH; Xie XS; Sun H; Sun L; Wan DM; Liu YF; Jiang ZX; Guo R
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1606-1609. PubMed ID: 34627448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The predictive value of serum free light chain level early after allogeneic hematopoietic stem cell transplantation for chronic graft-versus-host disease, a preliminary study.
    Wang B; Liang Z; Liu W; Sun Y; Cen X; Dong Y; Ren H
    Clin Transplant; 2020 Jul; 34(7):e13865. PubMed ID: 32242991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXCL9 Predicts Severity at the Onset of Chronic Graft-versus-host Disease.
    Giesen N; Schwarzbich MA; Dischinger K; Becker N; Hummel M; Benner A; Radujkovic A; Müller-Tidow C; Dreger P; Luft T
    Transplantation; 2020 Nov; 104(11):2354-2359. PubMed ID: 31929430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Graft-Versus-Host-Disease and Health-Related Quality of Life in Young Long-term Survivors of Cancer and Allogeneic Hematopoietic Stem Cell Transplantation.
    Diep PP; Rueegg CS; Burman MM; Brinch L; Bø K; Fosså K; Landrø L; Loge JH; Lund MB; Massey RJ; Myrdal OH; Pathak M; Rimstad L; Tanem KE; Tjønnfjord GE; Aaløkken TM; Ruud E
    J Adolesc Young Adult Oncol; 2023 Feb; 12(1):66-75. PubMed ID: 35544321
    [No Abstract]   [Full Text] [Related]  

  • 7. Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.
    Fraile P; Vazquez L; Caballero D; Garcia-Cosmes P; López L; San Miguel J; Tabernero JM
    Eur J Haematol; 2013 Aug; 91(2):129-34. PubMed ID: 23710658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential value of autoantibodies as biomarkers of chronic graft-versus-host disease after allogeneic stem cell transplantation.
    Hao B; Gao S; Sang YW; Wang L; Meng XQ; You JY
    J Zhejiang Univ Sci B; 2019 Oct.; 20(10):849-860. PubMed ID: 31489804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
    Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of chemotherapy combined with donor lymphocyte infusion on chronic graft-versus-host disease and prognosis in minimal residual disease positive patients after allogeneic hematopoietic stem cell transplantation].
    Shi YX; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YY; Liu KY; Huang XJ; Mo XD
    Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):713-719. PubMed ID: 31648470
    [No Abstract]   [Full Text] [Related]  

  • 11. Sarcopenia among patients after allogeneic hematopoietic stem cell transplantation and the impact of chronic graft-versus-host disease.
    Ljubas Kelecic D; Lelas A; Karas I; Desnica L; Vukic T; Sabol I; Vranesic Bender D; Serventi Seiwerth R; Peric Z; Durakovic N; Vitali Cepo D; Vrhovac R; Nemet D; Pavletic S; Pulanic D; Krznaric Z
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2967-2978. PubMed ID: 32507973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The clinical characteristics of polyserositis as main presentation of chronic graft-versus-host rejection disease after allogeneic hematopoietic stem cell transplantation].
    Wang Q; Li Y; Qiu Z; Xu W; Sun Y; Wang L; Wang M; Liu W; Dong Y; Ou J; Wang W; Liang Z; Wang Q; Cen X; Ren H
    Zhonghua Nei Ke Za Zhi; 2014 May; 53(5):394-7. PubMed ID: 25146408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and risk of chronic graft-versus-host disease of liver in allogeneic hematopoietic stem cell transplant recipients.
    Chen CT; Liu CY; Yu YB; Liu CJ; Hsiao LT; Gau JP; Chiou TJ; Liu JH; Liu YC
    PLoS One; 2017; 12(9):e0185210. PubMed ID: 28934311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pentraxin-3 levels in graft-versus-host disease during allogeneic hematopoietic stem cell transplantation.
    Doehn JM; Winkler A; Kuzmina Z; Hladik A; Greinix H; Knapp S; Robak O
    Exp Hematol; 2016 Oct; 44(10):917-23. PubMed ID: 27403536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Ro52 Autoantibodies Are Related to Chronic Graft-vs.-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.
    Yang K; Chen Y; Qi H; Ye Y; Fan Z; Huang F; Zhang H; Suo Y; Liu Q; Jin H
    Front Immunol; 2020; 11():1505. PubMed ID: 32849514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of Foxp3+ T cell subsets involved in incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Hu Y; Cui Q; Ye Y; Luo Y; Tan Y; Shi J; Huang H
    Hematol Oncol; 2017 Mar; 35(1):118-124. PubMed ID: 26439896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
    Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances and research progress in biomarkers for chronic graft versus host disease.
    Ji R; Li Y; Huang R; Xiong J; Wang X; Zhang X
    Crit Rev Oncol Hematol; 2023 Jun; 186():103993. PubMed ID: 37061073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Association of the ratio of regulatory and effector T cells with recurrence and chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].
    Wang HT; Zhao XY; Zhao XS; Han TT; Lv M; Chang YJ; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):679-84. PubMed ID: 23978019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validated graft-specific biomarkers identify patients at risk for chronic graft-versus-host disease and death.
    Logan BR; Fu D; Howard A; Fei M; Kou J; Little MR; Adom D; Mohamed FA; Blazar BR; Gafken PR; Paczesny S
    J Clin Invest; 2023 Aug; 133(15):. PubMed ID: 37526081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.